Applying Synthetic Lethality for the Selective Targeting of Cancer
Top Cited Papers
- 30 October 2014
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 371 (18), 1725-1735
- https://doi.org/10.1056/nejmra1407390
Abstract
Synthetic lethality refers to the requirement that two defects be present for cell death to occur. When an agent damages DNA, its effects on the cell can be amplified if the efforts of the cell to repair the damage are inhibited. Clinical application of this idea is just beginning.Keywords
This publication has 73 references indexed in Scilit:
- Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategiesCell Research, 2012
- Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling NetworksCell, 2012
- DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1Cancer Cell, 2010
- The DNA-damage response in human biology and diseaseNature, 2009
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2EMBO Molecular Medicine, 2009
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras OncogeneCell, 2009
- Variation of Breast Cancer Risk Among BRCA1/2 CarriersJAMA, 2008
- Molecular Mechanisms of Mammalian Global Genome Nucleotide Excision RepairChemical Reviews, 2005
- Identification of a RING protein that can interact in vivo with the BRCA1 gene productNature Genetics, 1996